XSTO
PILA
Market cap9mUSD
May 28, Last price
3.23SEK
1D
2.54%
1Q
-11.75%
IPO
-64.03%
Name
Pila Pharma AB
Chart & Performance
P/E
—
P/S
113.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.66%
Rev. gr., 5y
17.47%
Revenues
775k
-47.03%
Net income
-11m
L+13.20%
CFO
-8m
L+61.17%
Profile
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 775 -47.03% | 1,463 -22.21% | 1,881 161.49% | |||||||
Cost of revenue | 10,770 | |||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 775 | 1,463 | (8,889) | |||||||
NOPBT Margin | 100.00% | 100.00% | ||||||||
Operating Taxes | 17,886 | |||||||||
Tax Rate | ||||||||||
NOPAT | 775 | 1,463 | (26,775) | |||||||
Net income | (11,241) 13.20% | (9,930) -77.77% | (44,663) 77.56% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 9,841 | 8,562 | 6,011 | |||||||
BB yield | -11.03% | -25.36% | -11.26% | |||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,000 | |||||||||
Net debt | (4,893) | (6,019) | (7,307) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (7,823) | (4,854) | (9,091) | |||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 6,761 | 3,565 | (11,875) | |||||||
FCF | 775 | 1,463 | (26,759) | |||||||
| Balance | ||||||||||
Cash | 4,893 | 5,954 | 7,242 | |||||||
Long term investments | 65 | 65 | ||||||||
Excess cash | 4,854 | 5,946 | 7,213 | |||||||
Stockholders' equity | (92,325) | (81,226) | (71,527) | |||||||
Invested Capital | 97,587 | 87,888 | 80,929 | |||||||
ROIC | 0.84% | 1.73% | ||||||||
ROCE | 14.73% | 21.96% | ||||||||
| EV | ||||||||||
Common stock shares outstanding | 23,793 | 21,100 | 17,254 | |||||||
Price | 3.75 134.38% | 1.60 -48.30% | 3.10 -54.49% | |||||||
Market cap | 89,225 164.29% | 33,761 -36.78% | 53,401 -41.39% | |||||||
EV | 84,332 | 27,741 | 46,093 | |||||||
EBITDA | 775 | 2,540 | (8,874) | |||||||
EV/EBITDA | 108.82 | 10.92 | ||||||||
Interest | 53 | 40 | 658 | |||||||
Interest/NOPBT | 6.84% | 2.74% | ||||||||